5-氨基甲基-2-糠酸乙酯 | 18707-63-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-氨基甲基-2-糠酸乙酯
• 中文别名: 5-(氨基甲基)-糠酸盐酸盐乙基；5-(氨基甲基)呋喃-2-羧酸乙酯；5-(氨基甲基)呋喃-2-甲酸乙酯；呋喃-2-羧酸,5-氨基甲基-,乙酯；5-(氨基甲基)-2-呋喃羧酸乙酯
• 英文名称: ethyl 5-(aminomethyl)furan-2-carboxylate
• 英文别名: 5-Aminomethyl-2-furancarbonsaeureethylester
• CAS: 18707-63-6
• 化学式: C₈H₁₁NO₃
• mdl: MFCD02906319
• 分子量: 169.18
• InChiKey: GSWZGDLAZFBBPB-UHFFFAOYSA-N

物化性质

• 沸点：
  278.5±30.0 °C(Predicted)
• 密度：
  1.153±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  5-氨基甲基-2-糠酸乙酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 1-羟基苯并三唑 、 caesium carbonate 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-({4-[({[5-(4-methoxypyridin-3-yl)-1H-indazol-3-yl]carbonyl}amino)methyl]piperidin-1-yl}methyl)furan-2-carboxylic acid
  参考文献：
  名称：

  Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders

  摘要：

  Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3 beta (GSK-3 beta) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3 beta inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3 beta. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3 beta inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3 beta inhibitors as new tools in the development of new treatments for mood disorders

  DOI：

  10.1021/acs.jmedchem.5b01208
• 作为产物：
  描述：

  5-氯甲基-2-呋喃甲酸乙酯 在 sodium azide 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-氨基甲基-2-糠酸乙酯
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
  [FR] COMPOSITIONS ET MÉTHODES LES UTILISANT POUR LE TRAITEMENT D'UNE MALADIE NEURODÉGÉNÉRATIVE ET MITOCHONDRIALE

  摘要：

  本公开涉及部分化合物或其药用盐，用于治疗和/或预防神经退行性疾病、线粒体疾病、纤维化和/或心肌病。

  公开号：

  WO2018237145A1

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• PYRAZOLE COMPOUNDS AND USE THEREOF
  申请人：Takagi Masaki

  公开号：US20090036450A1

  公开（公告）日：2009-02-05

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。
• Cascade of the Hinsberg / IMDAF reactions in the synthesis 2-arylsulfonyl-3a,6-epoxyisoindoles and 4a,7-epoxyisoquinolines in water
  作者：Maryana A. Nadirova、Anastasia V. Khanova、Fedor I. Zubkov、Dmitriy F. Mertsalov、Irina A. Kolesnik、Sergey K. Petkevich、Vladimir I. Potkin、Anton A. Shetnev、Sofia I. Presnukhina、Anna A. Sinelshchikova、Mikhail S. Grigoriev、Vladimir P. Zaytsev

  DOI：10.1016/j.tet.2021.132032

  日期：2021.4

  formation of a 3a,6-epoxyisoindole core in one synthetic stage. Usually, in boiling water, the interaction sequence involves two consecutive steps: the Hinsberg reaction and the intramolecular Diels–Alder furanе (IMDAF) reaction. The scope and limitations of the proposed method were thoroughly investigated, and it was revealed that the key [4 + 2] cycloaddition step proceeds through an exo-transition state

  可以从相应的糠醛或糠胺中容易获得的N-糠基烯丙基胺在一个合成阶段中与多种芳基磺酰氯发生反应，形成3a，6-环氧异吲哚核。通常，在沸水中，相互作用序列涉及两个连续的步骤：Hinsberg反应和分子内Diels-AlderFuranе（IMDAF）反应。彻底研究了所提出方法的范围和局限性，并且揭示了关键的[4 + 2]环加成步骤是通过外向过渡态进行的，从而导致目标杂环的单一非对映异构体的排他性形成。该方法允许获得N-硫磺基取代的3a，6-环氧异吲哚和4a，7-环氧异喹啉，它们对于进一步转化和随后的生物筛选，特别是抗菌活性，可能是有用的底物。
• ORGANIC COMPOUNDS
  申请人：Dales Natalie

  公开号：US20090156615A1

  公开（公告）日：2009-06-18

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A去饱和酶活性的方法以及包含这些衍生物的药物组合物。
• OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF
  申请人：Hahn Michael

  公开号：US20110034450A1

  公开（公告）日：2011-02-10

  The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及具有氧代取代的氮杂杂环部分结构的新型羧酸衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病的用途。